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Abstract
Introduction Active surveillance is a strategy for
managing low-risk, localised prostate cancer, where
men are observed with serial prostate-specific antigen
assessments to identify signs of disease progression.
Currently, there are no strategies to support active
surveillance compliance nor are there interventions that
can prevent or slow disease progression, ultimately
delaying transition to active treatment before it is clinically
required. Recently, we proposed that exercise may have
a therapeutic potential in delaying the need for active
treatment in men on active surveillance.
Methods and analysis A single-blinded, two arm,
multicentre randomised controlled trial will be undertaken
with 168 patients randomly allocated in a ratio of 1:1 to
exercise or usual care. Exercise will consist of supervised
resistance and aerobic exercise performed three times per
week for the first 6 months in an exercise clinical setting,
and during months 7–12, a progressive stepped down
approach will be used with men transitioning to once a
week supervised training. Thereafter, for months 13 to
36, the men will self-manage their exercise programme.
The primary endpoint will be the time until the patients
begin active therapy. Secondary endpoints include disease
progression (prostate specific antigen), body composition
and muscle density, quality of life, distress and anxiety and
an economic analysis will be performed. Measurements
will be undertaken at 6 and 12 months (postintervention)
and at 24 and 36 months follow-up. The primary outcome
(time to initiation of curative therapy) will be analysed
using Cox proportional hazards regression. Outcomes
measured repeatedly will be analysed using mixed effects
models to examine between-group differences. Data will
be analysed using an intention-to-treat approach.
Ethics and dissemination Outcomes from the study
will be published in peer-reviewed academic journals and
presented in scientific, consumer and clinical meetings.
Trial registration number ACTRN12618000225213.

Introduction
Prostate cancer (PCa) is a major challenge
for our health system and its workforce and
for Australian society as a whole. In 2017,

Strengths and limitations of this study
►► This is a novel multicentre randomised controlled

trial of 12-month supervised resistance and aerobic exercise versus usual care in men with prostate
cancer on active surveillance, with subsequent follow-up of over 2 years to monitor therapeutic progression and psychological well-being.
►► The study proposed here will determine the efficacy of a comprehensive exercise programme during
active surveillance in delaying or preventing patient
morbidity associated with prostate cancer primary
therapy. Savings to the health and medical system
could be extensive with any delay in prostatectomy, radiation therapy or androgen deprivation
therapy, reducing costs of current overtreatment
substantially.
►► The study will be undertaken in the Australian clinical setting of prostate cancer care, and differences in active surveillance and disease progression
definitions may exist within the context of other
countries.

more than 200 000 Australian men were
living with PCa, 80% of them were longterm survivors.1 2 The widespread prostate-specific antigen (PSA) screening for
PCa has led to concerns about the overdiagnosis and overtreatment of this disease with
the overdiagnosis estimated to be as high as
67%.3 Overtreatment rates are also high with
reports of 80% of men receiving treatments
on initial diagnosis.4 Active surveillance (AS)
is a strategy for managing low-risk localised
PCa, where men are observed with regularly
schedule serial PSA assessments to identify
signs of disease progression.5 AS reduces overtreatment in clinically insignificant disease,5
reducing PCa burden for the individual, the
healthcare system and the society. Problematically, most men will not comply with AS and
those who convert to active treatment too
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soon. Currently there are no strategies to (1) support AS
compliance applying a lifestyle approach or (2) prevent or
slow disease progression, ultimately delaying transition to
active treatment before it is clinically required.5–10 These
are the two critical unanswered questions in applying AS
to men with PCa.
We recently presented a preliminary evidence6 that
exercise may have therapeutic potential in delaying the
need for active treatment (eg, surgery/radiation) in men
on AS. Exercise is implicated in decreasing the number of
patients undergoing active treatment,11 reducing PSA,12
as well as modulating the biological processes involved
with tumourigenesis.13 It may act through systemic mechanisms, as exercise alters circulating factors that inhibit
PCa cell proliferation in vitro.14–16 Further, increased
adiposity is associated with increased risk of PCa
2

progression specifically during AS,17 and exercise can be
an effective countermeasure to this in the setting of AS
(figure 1).6
Exercise as a therapeutic intervention in such men may
also have important additional benefits by addressing
other adverse consequences. The psychological burden
of AS, in terms of cancer-related anxiety, also influences
adherence and treatment decisions as much as clinical
disease progression.18 Not treating a cancer runs against
the norm and the surveillance process is inherently
stressful. Exercise presents as a supportive care approach
that closely maps onto core male values and has the potential to both combat illness but also help prevent and/or
minimise anxiety and uncertainty related to living with
a PCa diagnosis. Specifically, by supporting male values
around strength, self-reliance and action,19 exercise may
Galvão DA, et al. BMJ Open 2018;8:e022331. doi:10.1136/bmjopen-2018-022331
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Figure 1 Proposed mechanisms of exercise on prostate cancer and disease progression. Reprinted with permission from
Galvao et al.6
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Study design (1 year intervention and 1 and 2 years follow-up).

increase men’s self-efficacy or feelings of control over
their health, and thereby support adherence to AS while
improving psychological outcomes and physical and
mental quality of life (QoL).6 20
To characterise and quantify the benefits of exercise
for men on AS, we propose to undertake a multicentre
randomised controlled trial (RCT) of 12-month supervised resistance and aerobic exercise versus usual care in
men with PCa on AS, with subsequent follow-up of over 2
years to monitor therapeutic progression and psychological well-being.
Methods and analysis
This is a single-blinded (investigators blinded to group
allocation), two-arm, multicentre RCT that will examine
the efficacy of combined resistance and aerobic exercise
during AS on disease progression in men with low-risk
PCa. An ‘exercise’ group will complete a 6-month supervised exercise intervention followed by a stepped down
programme for 6 months and a subsequent self-managed
maintenance programme for 2 years (figure 2). A ‘usual
care’ group will maintain usual medical care and receive
standard information on current physical activity guidelines for cancer survivors, which will include an unsupervised walking programme.
Patients and methods
One hundred and sixty-eight men (84 patients per arm)
within 1 year of diagnosis of PCa and undergoing AS will
be recruited by invitation of their attending specialist from
two Australian cities (Perth and Melbourne). Patients suitable for AS will be selected from the Multi-Disciplinary
Uro-Oncology meeting at the recruiting site. Inclusion
criteria are: (1) histologically proven adenocarcinoma of
the prostate, (2) no prior therapy for PCa, (3) fit for curative intent therapy, (4) willing to attend follow-up, (5) clinical stage <T2, (6)<10% Gleason pattern 4 disease on biopsy
and (7) PSA ≤10 ng/mL. Exclusion criteria are: (1) already
performing regular exercise defined as undertaking structured resistance and aerobic training two or more times
per week within the past 3 months, (2) acute illness or any
musculoskeletal, cardiovascular or neurological disorder
that could inhibit exercise performance or put participants
at risk from exercising, (3) variant histopathology (small
cell, intraductal, sarcomatoid), presence of extraprostatic extension or lymphovascular invasion, (4) patient no
longer considered a candidate for curative intent treatment
and (5) intention to move place of residence away from
the two study sites. Eligible patients will undertake baseline
Galvão DA, et al. BMJ Open 2018;8:e022331. doi:10.1136/bmjopen-2018-022331

measurements prior to randomisation. All patients must
provide written informed consent prior to participation in
addition to a physician consent form. The study coordinator
will obtain the consent forms from patients and physicians.
All data relevant to the study will be kept on password-encrypted computers accessible only by study investigators
situated in the Exercise Medicine Research Institute (Perth,
WA, Australia).
Patient and public involvement
We work closely with the Prostate Cancer Foundation of
Australia (PCFA), their support groups and state offices.
PCFA and support groups have been involved in the
development of this proposal and will maintain a very
important role on this project in patient recruitment and
support as well as translation and dissemination of the
research findings. We have used this feedback to inform
this project and ensure that it engages participants in
a respectful, ethical and impactful way. As the project
evolves, PCFA will assist in the dissemination of findings
to cancer support groups and the general public, while
study participants will receive their individual results as
well as overall study findings.
Randomisation
Patients will be randomly allocated in a ratio of 1:1 to
the two study arms, and will be stratified according to:
(1) age (<60 years≥), (2) PSA (<5≥) and (3) time on AS
(<6 months≥). Within each stratum, randomisation will
occur in blocks of either 8 or 10, with block size randomly
selected in a 1:1 ratio. Patients will be randomised via a
central web-based service (Griffith University) to ensure
allocation concealment until study entry. Randomisation
will occur immediately after each patient completes their
baseline questionnaire (figure 3). The study coordinator
will assign participants to groups.
Measurements
All measurement study endpoints will take place at baseline,
6 months, postintervention (12 months) and 1 and 2-year
follow-up (months 24 and 36). All assessment tools/procedures have established validity and reliability and are used
widely in clinical research including by our team.
Primary study endpoint
Patients undergoing active therapy
The number of patients undergoing active therapy
(radical prostatectomy, radiotherapy or androgen deprivation) and the time they began active therapy will be
extracted directly from the urologist clinical investigators
3
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CONSORT diagram. CONSORT, Consolidated Standards of Reporting Trials.

as part of their routine clinical practice; therefore, all
patients will be captured. Data will be extracted for the
3 years following randomisation, and the reasons for
progression to active therapy will be recorded.
Secondary study endpoints
Disease progression (PSA)
For all patients, PSA will be measured commercially by
an Australian National Association of Testing Authorities
accredited laboratory.21
Body composition and muscle density
Regional and whole-body lean mass and fat mass will
be derived from the whole-body dual-energy X-ray
4

absorptiometry scans. Trunk adiposity, visceral fat and
adipose indices will be assessed using standard procedures.21–23 Peripheral quantitative CT will be used to
measure muscle density (an indicator of fat infiltration
within the muscle) and muscle cross-sectional areas of the
lower limbs.24
QoL, prostate cancer-specific distress, overall psychological
distress and PSA anxiety
Health-related QoL will be assessed using the Medical
Outcomes Short Form 36 (SF-36v2).25 A three-item cancer
standardised anxiety scale developed by Latini et al18 will
assess men’s fears about cancer recurrence. This scale has
Galvão DA, et al. BMJ Open 2018;8:e022331. doi:10.1136/bmjopen-2018-022331
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Economic analysis
An alongside trial economic evaluation will be undertaken to assess the health benefits and additional costs
compared with usual care. This will inform the relative
value for money of exercise compared with other healthcare interventions in this group of men with PCa. Hospital
resource use and associated costs will be obtained to assess
costs for secondary healthcare for the exercise and usual
care groups. All hospital events, including emergency
department attendances, outpatient visits and procedures
and inpatient admission for all causes will be sought.
These data are important to identify potential PCa-related
events as well as identifying total healthcare resource use.
In addition, the costs for providing the exercise intervention will be identified through the study. Data on health
benefits and costs will be adjusted for covariates such as
age, key comorbidities (eg, diabetes), body mass index
and so forth. Health benefits will be measured as quality
of life via the SF-36v2 and converted to a health utility
scale using the Australian SF-6D scoring algorithm.31
Costs associated with health resource use and the costs of
the intervention will be standardised to a common year
(eg, 2018). Incremental costs and benefits will then be
estimated and reported as the incremental cost utility
ratio (ICUR). The ICUR will be bootstrapped32 to identify
the 95% CIs, probability the intervention is good value for
money and the risk of anyone in the intervention group
not being better off. Deterministic sensitivity analysis will
be undertaken to identify the main drivers of the costs,
outcomes and value for money.
Effect mediators
The Masculinity in Chronic Disease Scale19 will assess the
extent to which men identify with six masculine values:
strength; sexual importance/priority; family responsibilities; emotional self-reliance; optimistic capacity and
action approach. This scale was developed for Australian
men with prostate cancer; has strong evidence of validity
in this target group and has been found to predict men’s
help seeking.33 The General Self-Efficacy Scale34 will
assess men’s perceptions that they can cope with stressful
life events. This scale has been used widely internationally
as a predictor of adaptation to adversity including cancer
treatment effects.20
Galvão DA, et al. BMJ Open 2018;8:e022331. doi:10.1136/bmjopen-2018-022331

Other measurements: physical function and physical activity levels
A battery of standard tests will be used to assess physical function: (1) 400 m walk (aerobic capacity), (2) one
repetition maximum for the leg press and chest press
(muscular strength) and (3) repeated chair rise (lower
body muscle function).21–23 Physical activity levels will
be assessed objectively over a 7-day period using a validated, reliable triaxial accelerometer activity monitor
(ActiGraph GT3X+).35 Self-reported physical activity will
be assessed by the leisure score index from the Godin
Leisure-Time Exercise Questionnaire.23 36 37
Safety and monitoring
Patients will be monitored for any adverse events during
training and testing by the exercise physiologists with
study clinicians overseeing all aspects of patient management where required.
Exercise intervention
The exercise intervention will consist of supervised
resistance and aerobic exercise performed over three
sessions per week for 6 months in an exercise clinic
setting. During months 7–12, the exercise intervention
group will transition to once a week supervised exercise
in a clinic for months 7–8, once every 2 weeks supervised
exercise in months 9–10 and once per month supervised
exercise in months 11–12. This step-down approach will
include a self-managed exercise programme consisting
of a booklet and training log with detailed information
about the exercise prescription and how to implement
in a variety of settings. Participants will be encouraged
and supported to continue their aerobic and resistance
exercise programme in their local fitness centre or other
exercise facilities where they can maintain a high-quality
exercise programme under their self-management. The
self-managed exercise programme is designed to replicate the exercises performed in the supervised sessions
and includes resistance, aerobic and flexibility exercises.
Finally, from month 13 to 36, the exercise programme
will exclusively consist of a self-managed programme
and has been implemented by our group previously in
a multicentre year-long trial in men with PCa on active
therapy.23 The initial programme will be supervised by
exercise physiologists in Perth and Melbourne.
The exercise programme is designed to provide optimal
stimulus to the cardiorespiratory and neuromuscular
systems while maximising safety, compliance and retention. The exercise sessions will be conducted in small
groups of up to 10–12 participants exercising in pairs
under direct supervision to ensure correct technique
and minimise the risk for injury. Resistance exercise will
involve 6–8 exercises that target the major upper and
lower body muscle groups. Intensity will be manipulated
from 6 to 12 repetition maximum (RM; ie, the maximal
weight that can be lifted 6 to 12 times which is equivalent
to ~60%–85% of 1RM) using one to four sets per exercise. The aerobic exercise component will include 20 to
30 min of moderate to vigorous intensity cardiovascular
5
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previously been found to predict receipt of active treatment independent of PSA velocity in a sample of men
on active surveillance.18 Overall cancer-specific distress
will be assessed by the Impact of Events Scale revised26
which has been used extensively by our team and is valid
and reliable in patients with prostate cancer.27 28 The Brief
Symptom Inventory-18 will be used to assess psychological
distress across the following domains: anxiety, depression,
somatisation and global distress severity.29 Antidepressant
use will be recorded. The Memorial Anxiety Scale for
Prostate Cancer will be used to assess anxiety specifically
focused on PSA testing (the PSA Anxiety Subscale).30

Open Access

Usual care
The usual care group will receive an unsupervised walking
programme and an educational booklet outlining the
current national physical activity recommendation for
cancer survivors along with a logbook to record their
physical activity. During the study, both groups will be
encouraged to maintain customary dietary patterns and
the Mini Nutritional Assessment will be used to monitor
nutritional status.49
Calculation of sample size
The target sample size of 168 patients is based on having
80% power to be able to detect a HR of undergoing
curative therapy in the exercise intervention group,
compared with the usual care group, of 0.35 or smaller
(alpha=0.05). This is equivalent to a difference between
25% of the usual care group undergoing curative therapy
within 3 years postrandomisation versus <10% in the
group undertaking the exercise intervention.11 A difference of this magnitude has been recommended by our
practice clinicians to be clinically important. This sample
size accounts for a possible 5% dropout due to clinical
records not being available at study completion. This
sample size will give us sufficient power to examine our
secondary outcomes of interest. For example, for muscle
mass we will have >80% power to detect differences
between groups of 0.8 kg or greater at 6 months postintervention, assuming an SD for change of ~1.5 kg and
30% loss to follow-up (due to the need for participants
to represent to the study team for this outcome to be
measured).21
Statistical analysis
The primary outcome, initiation of curative therapy, will
be analysed using Cox proportional hazards regression,
with treatment group (exercise intervention/usual care)
6

entered as the main effect. If data do not meet the proportional hazards assumption, the log-rank test will be used.
Outcomes measured repeatedly will be analysed using
mixed-effects models to examine differences between
groups over time, with treatment group and time included
as main effects, as well as an intervention-by-time interaction term. The patient will be included as a random effect
to account for the non-independence of observations
from the same participant. Continuous outcomes will
be analysed using linear models, binary outcomes with
logistic models and count outcomes with Poisson models.
Depending on the balance between groups postrandomisation, clinically relevant covariates will be included in the
models where appropriate. Data will be analysed using an
intention-to-treat approach. Tests will be two tailed and
an alpha level of 0.05 will be applied as the criterion for
statistical significance.
Ethics and dissemination
Outcomes from the study will be published in peer-reviewed academic journals and presented in scientific,
consumer and clinical meetings. The study investigators
and trial coordinator will have access to the data.
Discussion
PCa is a financial burden to men and their families and
our health system. In 2008 and 2009, this was the top male
cancer cost to the health system in Australia, totalling
$A347 million or 14% of total male cancer expenditure.50
As PCa prevalence increases, the health system will find
it increasingly difficult to prioritise care in the absence
of clearly developed economic models. There is a deepening realisation by clinicians and patients that many
prostate cancers do not require active treatment, and in
fact, such interventions may result in devastating adverse
effects. Already, a considerably large number of patients
are referred for AS.7 51–53 Studies (including our previous
work) examining the role of exercise in PCa provide
strong evidence that beneficial effects are derived during
or following definitive therapy and exercise has recently
been included in the 2015 PCa Care Guideline: American
Society of Clinical Oncology Clinical Practice Guideline.7
There is, however, no information on and evidence base
for the efficacy of exercise medicine interventions during
AS in slowing disease progression, reducing anxiety and
distress and improving QoL. The study proposed here
would be the first to determine the efficacy of a comprehensive exercise programme during AS in substantially
delaying or preventing patient morbidity associated with
PCa primary therapy. Savings to the health and medical
system could be extensive with any delay in prostatectomy, radiation therapy or androgen deprivation therapy
reducing costs of current overtreatment substantially. If
proven efficacious in this stage of PCa management, exercise medicine could be immediately implemented as an
important component of clinical best practice, at minimal
Galvão DA, et al. BMJ Open 2018;8:e022331. doi:10.1136/bmjopen-2018-022331
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exercise (~60%–85% of estimated maximum heart rate)
using a variety of modes such as walking or jogging on
a treadmill, cycling or rowing on a stationary ergometer.
Participants will be encouraged to undertake additional
aerobic exercise outside the clinic sessions with the goal
of achieving a total of at least 150 min of moderate to
vigorous intensity aerobic exercise each week. Exercise
prescription will be progressive and modified according to
individual response. Both moderate intensity continuous
and high-intensity interval training will be implemented
to provide greater variety and training stimulus. To reduce
the possibility of boredom and over-reaching, the exercise programme will be periodised by cycling emphasis on
intensity and volume. We have used this exercise prescription effectively in previous trials involving men with PCa
and have reported significant improvements in quality
of life, lean muscle mass, fatigue, aerobic capacity and
physical function.21 23 38–48 The step-down approach to
self-management is intended to maximise the translation
of this intervention to best practice management of this
patient population.
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